Department of Medicine
Robert Wieder, M.D., Ph.D.
University Hospital, Newark
Insurance Participation: with Provider Number ( where applicable ) The information below is subject to change and should not be relied upon until after it is verified with the insurance company. In addition, psychiatric providers should be contacted directly for information on their participation with managed care and insurance companies.
Awards & Achievements
Outstanding Breast Cancer Researcher Award, State of New Jersey Commission on Cancer Research, Clinical Sciences Faculty of the Year Award, UMDNJ-NJMS Faculty Association 2001
Robert Wieder, MD, PhD
Research: Our laboratory studies the mechanisms of dormancy and resistance to chemotherapy in breast cancer cells that metastasize to the bone marrow.
Sri Harikrishna Vellanki, PhD
M.D., 1983, Mount Sinai School of Medicine of New York
Ph.D., 1982, Mount Sinai School of Medicine of New York
Licensure & Certification
Areas of Interest
Our laboratory studies the mechanisms of dormancy and resistance to chemotherapy in breast cancer cells that metastasize to the bone marrow. In a model of dormancy we demonstrated that well differentiated breast cancer cells that metastasize to the bone marrow are affected by growth factors present in the bone marrow stroma, that include basic fibroblast growth factor (FGF-2). FGF-2 induces a state of dormancy in well differentiated breast cancer cells that includes growth arrest in the G1 phase of the cell cycle and a change in the cellular integrin repertoire. Through an upregulated integrin alpha 5 beta 1, the cells receive specific survival signaling through a number of singaling pathways, that include the PI3K/Akt pathway. A number of other signaling pathways that engage in crosstalk contribute to the survival of these cells. Our current efforts are directed at understanding the mechanism of activation and crosstalk among a number of these pathways, with an emphasis on the small GTPase Rho.
Our interests also include understanding the mechanisms of cell death signaling by chemotherapy agents and the effects of retinoids and deltanoids in potentiating these cell death signaling pathways. These laboratory investigations are being translated into clinical trials.